lncRNA RP11-838N2.3 Promoted Cisplatin Resistance in Lung Adenocarcinoma

Figure 11

RP11-838N2.3 knockdown could not affect the cell cycle of A549/DDP. (a) A549/DDP shRNA-NC. (b) A549/DDP shRNA. (c) A549/DDP shRNA-NC+2 μg/ml cisplatin. (d) A549/DDP shRNA+2 μg/ml cisplatin. (e) Compared with those in the A549/DDP shRNA-NC group, the cell ratios in the A549/DDP shRNA group in the G0/G1 phase (,), S phase (, ), and G2/M phase (, ) were not evidently different. Under the action of cisplatin, compared with those in the A549/DDP shRNA-NC+2 μg/ml cisplatin group, the cell ratios in the A549/DDP shRNA+2 μg/ml cisplatin group in the G0/G1 phase (, ), S phase (, ), and G2/M phase (, ) were not different. There were also no significant differences in the proportion of cells.

(a)

(b)

(c)

(d)

(e)